Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Principia Biopharma Inc. (“Principia” or the “Company”) (NASDAQ: PRNB)
to Sanofi (NASDAQ: SNY). Under the terms of the merger, Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash.
The Principia merger investigation concerns whether the Board of Principia has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.
To receive more information, please fill out the form.